Researchers are working on a new approach to target autoimmunity in the brain — a condition at the core of several diseases, including multiple sclerosis.

A genetically programmed living hydrogel material that facilitates intestinal wound healing is being considered for development as a probiotic therapy for patients with inflammatory bowel disease.